Treating Negative Symptoms in Schizophrenia: an Update
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
Interest in the negative symptoms of schizophrenia has increased rapidly over the last several decades, paralleling a growing interest in functional, in addition to clinical, recovery, and evidence underscoring the importance negative symptoms play in the former. Efforts continue to better define and measure negative symptoms, distinguish their impact from that of other symptom domains, and establish effective treatments as well as trials to assess these. Multiple interventions have been the subject of investigation, to date, including numerous pharmacological strategies, brain stimulation, and non-somatic approaches. Level and quality of evidence vary considerably, but to this point, no specific treatment can be recommended. This is particularly problematic for individuals burdened with negative symptoms in the face of mild or absent positive symptoms. Presently, clinicians will sometimes turn to interventions that are seen as more "benign" and in line with routine clinical practice. Strategies include use of atypical antipsychotics, ensuring the lowest possible antipsychotic dose that maintains control of positive symptoms (this can involve a shift from antipsychotic polypharmacy to monotherapy), possibly an antidepressant trial (given diagnostic uncertainty and the frequent use of these drugs in schizophrenia), and non-somatic interventions (e.g., cognitive behavioral therapy, CBT). The array and diversity of strategies currently under investigation highlight the lack of evidence-based treatments and our limited understanding regarding negative symptoms underlying etiology and pathophysiology. Their onset, which can precede the first psychotic break, also means that treatments are delayed. From this perspective, identification of biomarkers and/or endophenotypes permitting earlier diagnosis and intervention may serve to improve treatment efficacy as well as outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,856 · cited 1×
“As a result, it was postulated that these features would not be amenable to pharmacotherapy in the same fashion as positive symptoms [12].”
BackgroundDeficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332 · cited 1×
“, deficit) and secondary negative symptoms [3], although clinically”
BackgroundThe NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311 · cited 2×
“between primary and secondary negative symptoms is not essential [4].”
BackgroundFusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu170 · Cited by 683
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
BackgroundProvocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Bora, E., Lin, A., Wood, S. J., Yung, A. R., McGorry, P. D., & Pantelis, C. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12261 · Cited by 294 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
BackgroundNegative symptoms in individuals at clinical high risk of psychosis
Piskulic, D., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Heinssen, R., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., et al. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.018 · Cited by 282 · cited 1×
“To this last point, work focusing on the prodrome of schizophrenia indicates that deficit symptoms and cognitive impairment are evident by the time of the first psychotic break [8, 9], while enduring primary negative symptoms have been identified in approximately 25–30 % of individuals with chronic schizophrenia [10].”
BackgroundProspects for Minocycline Neuroprotection
Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276
Tsai, G., & Lin, P.-Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Lieberman, J. A., Davis, R. E., Correll, C. U., Goff, D. C., Kane, J. M., Tamminga, C. A., Mates, S., & Vanover, K. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.026 · Cited by 261
Freitas, C., Fregni, F., & Pascual-Leone, A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.027 · Cited by 251
Foussias, G., Agid, O., Fervaha, G., & Remington, G. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.017 · Cited by 250 · cited 1×
“avolition, asociality, and anhedonia [4, 5].”
Self-citationMinocycline to Improve Neurologic Outcome in Stroke (MINOS): A Dose-Finding Study
Fagan, S. C., Waller, J. L., Nichols, F. T., Edwards, D. J., Pettigrew, L. C., Clark, W. M., Hall, C. E., Switzer, J. A., Ergul, A., & Hess, D. C. (2010) · Stroke · doi:10.1161/strokeaha.110.582601 · Cited by 244
Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., Wallace, T. L., Knoflach, F., Dorflinger, E., Wettstein, J. G., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.163 · Cited by 234
Singh, S. P., Singh, V., Kar, N., & Chan, K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067710 · Cited by 223
The role of 5-HT2A receptors in antipsychotic activity
Schmidt, C. J., Sorensen, S. M., Kenne, J. H., Carr, A. A., & Palfreyman, M. G. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00210-w · Cited by 215
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.002 · Cited by 194
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
Predictors of recovery in first episode psychosis: The OPUS cohort at 10year follow-up
Austin, S. F., Mors, O., Secher, R. G., Hjorthøj, C. R., Albert, N., Bertelsen, M., Jensen, H., Jeppesen, P., Petersen, L., Randers, L., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.031 · Cited by 186 · cited 1×
“Resolution of positive symptoms, even in the early stages of schizophrenia, does not necessarily translate to functional recovery; figures suggest that full functional/social recovery occurs in less than 15 % of individuals with schizophrenia, with negative symptoms playing a significant role [7].”
BackgroundAlpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology
Pohanka, M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13022219 · Cited by 180
Wobrock, T., Guse, B., Cordes, J., Wölwer, W., Winterer, G., Gaebel, W., Langguth, B., Landgrebe, M., Eichhammer, P., Frank, E., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.009 · Cited by 170
Bersani, F. S., Minichino, A., Enticott, P. G., Mazzarini, L., Khan, N., Antonacci, G., Raccah, R. N., Salviati, M., Delle Chiaie, R., Bersani, G., et al. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2012.02.006 · Cited by 169
Duinkerke, S. J., Botter, P. A., Jansen, A. A. I., van Dongen, P. A. M., Haaften, A. J. V., Boom, A. J., Laarhoven, J. H. M. V., & Busard, H. L. S. M. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.4.451 · Cited by 164
CDP-choline: pharmacological and clinical review.
Takemura, M., Yamauchi, K., & Yamatodani, A. (1995) · PubMed · Cited by 157
Meyer, E. C., Carrion, R. E., Cornblatt, B. A., Addington, J., Cadenhead, K. S., Cannon, T. D., McGlashan, T. H., Perkins, D. O., Tsuang, M. T., Walker, E. F., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt235 · Cited by 154 · cited 1×
“At the same time, the relevance of both negative and cognitive symptoms in terms of functional recovery [2] has become central to rapidly expanding efforts focused on: (a) better understanding these domains and (b) establishing effective treatments.”
BackgroundClozapine resistance: Augmentation strategies
Porcelli, S., Balzarro, B., & Serretti, A. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.005 · Cited by 154
Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148
Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis
Shi, C., Yu, X., Cheung, E. F. C., Shum, D. H. K., & Chan, R. C. K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.019 · Cited by 144
Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Xie, L., Zhang, L., Yang, L., Yang, S., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.011 · Cited by 142
Dlabač-de Lange, J. J., Knegtering, R., & Aleman, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04808yel · Cited by 142
Stauffer, V. L., Millen, B. A., Andersen, S. W., Kinon, B. J., LaGrandeur, L., Lindenmayer, J., & Gomez, J. C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.020 · Cited by 140
Shirayama, Y., Hashimoto, K., Suzuki, Y., & Higuchi, T. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00367-x · Cited by 137
Akhondzadeh, S., Rezaei, F., Larijani, B. A., Nejatisafa, A., Kashani, L., & Abbasi, S. H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.008 · Cited by 136
Schilström, B., Ivanov, V., Wiker, C., & Svensson, T. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301087 · Cited by 134
Harvey, R. C., James, A. C., & Shields, G. (2016) · CNS Drugs · doi:10.1007/s40263-015-0308-1 · Cited by 134
Sepehry, A. A., Potvin, S., Elie, R., & Stip, É. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0417 · Cited by 116
The therapeutic promise of positive allosteric modulation of nicotinic receptors
Uteshev, V. V. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.072 · Cited by 113
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110
Ohgi, Y., Futamura, T., & Hashimoto, K. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150330143008 · Cited by 107
Defining and measuring negative symptoms of schizophrenia in clinical trials
Marder, S. R., & Kirkpatrick, B. W. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.016 · Cited by 107
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Lindenmayer, J., Nasrallah, H. A., Pucci, M. L., James, S., & Citrome, L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.019 · Cited by 104
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D., Vyas, G., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 102
Transcranial Direct Current Stimulation in Schizophrenia
Agarwal, S. M., Shivakumar, V., Bose, A., Subramaniam, A., Nawani, H., Chhabra, H., Sunil, V., Kalmady, S. V., Janardhanan, C. N., Narayanaswamy, et al. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.3.118 · Cited by 101
Choi, K.-H., Wykes, T., & Kurtz, M. M. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.107359 · Cited by 100
Walling, D., Marder, S. R., Kane, J., Fleischhacker, W. W., Keefe, R. S. E., Hosford, D. A., Dvergsten, C., Segreti, A. C., Beaver, J. S., Toler, S. M., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv072 · Cited by 97
Ko, Y., Jung, S.-W., Joe, S.-H., Lee, C. H., Jung, H.-G., Jung, I., Kim, S., & Lee, M. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.02.002 · Cited by 96
Antidepressants for the negative symptoms of schizophrenia
Rummel‐Kluge, C., Kissling, W., & Leucht, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005581.pub2 · Cited by 95
Unmet Needs in the Treatment of Schizophrenia: New Targets to Help Different Symptom Domains
Citrome, L. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13049su1c.04 · Cited by 93
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
Remington, G. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0334 · Cited by 89
Self-citationFusar-Poli, P., Kempton, M. J., & Rosenheck, R. A. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32835b091f · Cited by 89 · cited 1×
“Enthusiasm regarding the clinical benefits of SGAs for symptoms beyond psychosis has been tempered considerably based on accumulated evidence [1].”
BackgroundTargeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy
Deutsch, S. I., Schwartz, B. L., Schooler, N. R., Brown, C. H., Rosse, R. B., & Rosse, S. M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.023 · Cited by 86
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 85
Li, M.-L., Hu, X., Li, F., & Gao, W. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.012 · Cited by 84
Pharmacological treatment of negative symptoms in schizophrenia
Möller, H., & Czobor, P. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0596-y · Cited by 82
Hasan, A., Wolff-Menzler, C., Pfeiffer, S., Falkai, P., Weidinger, E., Jobst, A., Hoell, I., Malchow, B., Yeganeh-Doost, P., Strube, W., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0618-9 · Cited by 80
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
Ellaithy, A., Younkin, J., González‐Maeso, J., & Logothetis, D. E. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.06.002 · Cited by 80
Usall, J., Huerta‐Ramos, E., Labad, J., Cobo, J., Núñez, C., Creus, M., García–Parés, G., Cuadras, D., Franco, J. G., Miquel, E., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv149 · Cited by 79
Negative Correlation between Negative Symptoms of Schizophrenia and Testosterone Levels
GOYAL, R. O., SAGAR, R., AMMINI, A. C., KHURANA, M. L., & ALIAS, A. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1314.042 · Cited by 78
Akhondzadeh, S., Malek-Hosseini, M., Ghoreishi, A., Raznahan, M., & Rezazadeh, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.08.020 · Cited by 77
Ribeiz, S. R. I., Bassitt, D. P., Arrais, J., Ávila, R., Steffens, D. C., & Bottino, C. M. C. (2010) · CNS Drugs · doi:10.2165/11530260-000000000-00000 · Cited by 76
Chue, P., & Lalonde, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43404 · Cited by 76 · cited 1×
“Reference has been made to these drugs in other reviews of negative symptoms [13, 18], and, like ECT, these drugs have a long history of augmentation use in schizophrenia as well as specific subpopulations (e.”
BackgroundBeinat, C., Banister, S. D., Herrera, M., Law, V., & Kassiou, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0260-0 · Cited by 73
Oya, K., Kishi, T., & Iwata, N. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2426 · Cited by 69
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67
Acetylcholinesterase inhibitors for schizophrenia
Singh, J., Kour, K., & Jayaram, M. B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007967.pub2 · Cited by 67
Psychopharmacology of the negative symptoms: Current status and prospects for progress
Davis, M. C., Horan, W. P., & Marder, S. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.010 · Cited by 66
Rezaei, F., Mohammad-karimi, M., Seddighi, S., Modabbernia, A., Ashrafi, M., Salehi, B., Hammidi, S., Motasami, H., Hajiaghaee, R., Tabrizi, M. H., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b50a7 · Cited by 63
Dunlop, J., & Brandon, N. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565806 · Cited by 63
Iranpour, N., Zandifar, A., Farokhnia, M., Goguol, A., Yekehtaz, H., Ardakani, M. R. K., Salehi, B., Esalatmanesh, S., Zeionoddini, A., Mohammadinejad, P., et al. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2517 · Cited by 61
Kishi, T., & Iwata, N. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.013 · Cited by 60
Ritsner, M. S., Bawakny, H., & Kreinin, A. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12150 · Cited by 58
Dissecting negative symptoms in schizophrenia: Opportunities for translation into new treatments
Foussias, G., Siddiqui, I., Fervaha, G., Agid, O., & Remington, G. J. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114562092 · Cited by 58 · cited 1×
“It is now common to isolate different components under the framework of negative symptoms [6], but this strategy is in its earliest stages and it is unclear how these may differentially respond to treatment.”
BackgroundSelf-citationNeurosurgery for schizophrenia: an update on pathophysiology and a novel therapeutic target
Mikell, C. B., Sinha, S. R., & Sheth, S. A. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns15120 · Cited by 56
A Role for Oxytocin in the Etiology and Treatment of Schizophrenia
Rich, M. E., & Caldwell, H. K. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00090 · Cited by 55
Wierońska, J. M., Zorn, S. H., Doller, D., & Pilc, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.007 · Cited by 55
Oya, K., Matsuda, Y., Matsunaga, S., Kishi, T., & Iwata, N. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0634-9 · Cited by 54
Andrade, C., Kisely, S. R., Monteiro, I., & Rao, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.013 · Cited by 53
Huang, M., Felix, A. R., Flood, D. G., Bhuvaneswaran, C., Hilt, D. C., Koenig, G., & Meltzer, H. Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3596-0 · Cited by 52
Matosin, N., Fernandez, F., Lum, J. S., & Newell, K. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.003 · Cited by 52
Noroozıan, M., Ghasemi, S., Hosseini, S.-M.-R., Modabbernia, A., Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Rezaei, F., Salehi, B., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3064-2 · Cited by 50
Lasser, R. A., Dirks, B., Nasrallah, H. A., Kirsch, C., Gao, J., Pucci, M. L., Knesevich, M. A., & Lindenmayer, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.111 · Cited by 49
Left Dorsolateral Prefrontal Cortex Anodal tDCS Effects on Negative Symptoms in Schizophrenia
Gomes, J. S., Shiozawa, P., Dias, Á. M., Ducos, D. V., Akiba, H. T., Trevizol, A. P., Bikson, M., Aboseria, M., Gadelha, A., de Lacerda, A. L. T., et al. (2015) · Brain stimulation · doi:10.1016/j.brs.2015.07.033 · Cited by 49
Quan, W. X., Zhu, X. L., Qiao, H., Zhang, W. F., Tan, S., Zhou, D. F., & Wang, X. Q. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.029 · Cited by 47
Kishi, T., Mukai, T., Matsuda, Y., & Iwata, N. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8251-0 · Cited by 46
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Singer, P., Dubroqua, S., & Yee, B. K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150724100952 · Cited by 46
Ghanizadeh, A., Dehbozorgi, S., OmraniSigaroodi, M., & Rezaei, Z. (2014) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/1872213x08666141029123524 · Cited by 42
Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
GOFF, D. C. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000152 · Cited by 41
Compton, M. T., Bakeman, R. A., Alolayan, Y., Balducci, P. M., Bernardini, F., Broussard, B., Crisafio, A., Cristofaro, S. L., Amar, P., Johnson, S., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.028 · Cited by 41
Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia
Wallace, T. L., & Bertrand, D. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.08.003 · Cited by 41
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. U. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 38
Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms
Schooler, N. R., Buchanan, R. W., LAUGHREN, T. P., Leucht, S., Nasrallah, H. A., Potkin, S. G., Abi‐Saab, D., Berardo, C. G., Bugarski‐Kirola, D., Blaettler, T., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.001 · Cited by 37
Wegener, G. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00567.x · Cited by 34
Pawełczyk, T., Kołodziej–Kowalska, E., Pawełczyk, A. M., & Rabe‐Jabłońska, J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.071 · Cited by 33
Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 32
Přikryl, R., & Kučerová, H. P. (2013) · Journal of Ect · doi:10.1097/yct.0b013e318270295f · Cited by 30
Anti-inflammatory strategies in the treatment of schizophrenia
Andrade, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1095086 · Cited by 26
LaCrosse, A., Burrows, B. T., Angulo, R. M., Conrad, P. R., Himes, S. M., Mathews, N., Wegner, S. A., Taylor, S. B., & Olive, M. F. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3653-8 · Cited by 26
Relation Between Estradiol and Negative Symptoms in Men With Schizophrenia
Kaneda, Y., & Ohmori, T. (2005) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.17.2.239 · Cited by 26
Tossell, J. W., Greenstein, D. K., Davidson, A. L., Job, S. B., Gochman, P., Lenane, M., Nugent III, T. F., Gogtay, N., Sporn, A. L., & Rapoport, J. L. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.448 · Cited by 25
Levine, S. Z., & Leucht, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.005 · Cited by 22
Luther, L., Fukui, S., Firmin, R. L., McGuire, A. B., White, D. A., Minor, K. S., & Salyers, M. P. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.022 · Cited by 22
Fekadu, A., Mesfin, M., Medhin, G., Alem, A., Teferra, S., Gebre-Eyesus, T., Seboxa, T., Assefa, A., Hussein, J., Lemma, M. T., et al. (2013) · Trials · doi:10.1186/1745-6215-14-406 · Cited by 22
Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia
Qurashi, I., Collins, J., Chaudhry, I. B., & Husain, N. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527358 · Cited by 22
Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology.
Strous, R. D. (2005) · PubMed · Cited by 22
Vidal, C., Reese, C., Fischer, B. A., Chiappelli, J., & Himelhoch, S. S. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.vire.030813 · Cited by 20
Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor
Shafti, S. S., Jafarabad, M. S., & Azizi, R. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315591953 · Cited by 19
Do antidepressants improve negative symptoms in schizophrenia?
Barnes, T. R. E., & Paton, C. (2011) · BMJ · doi:10.1136/bmj.d3371 · Cited by 19
Kardashev, A., Ratner, Y., & Ritsner, M. S. (2018) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.kara.070415 · Cited by 18
Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil
Shafti, S. S., & Akbari, S. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000437 · Cited by 17
Chaudhry, I. B., Husain, N., Rahman, R.-U., Husain, M. O., Hamirani, M. M., Kazmi, A., Baig, S., Haddad, P. M., Buch, M. H., Qureshi, I., et al. (2015) · Trials · doi:10.1186/1745-6215-16-9 · Cited by 17
Park, S., & Lee, M.-K. (2014) · PubMed · Cited by 15
Lisiecka, D. M., Suckling, J., Barnes, T. R. E., Chaudhry, I. B., Dazzan, P., Husain, N., Jones, P. B., Joyce, E. M., Lawrie, S. M., Upthegrove, R., et al. (2015) · Trials · doi:10.1186/s13063-015-0580-x · Cited by 14
Repetitive transcranial magnetic stimulation and treatment of negative symptoms of schizophrenia.
Přikryl, R. (2011) · PubMed · Cited by 12
Effects of Atorvastatin on Negative Sign in Chronic Schizophrenia: a Double Blind Clinical Trial.
Sayyah, M., Boostani, H., Ashrafpoori, M., & Pakseresht, S. (2015) · Europe PMC (PubMed Central) · Cited by 10
Lee, S.-Y., Chen, S., Chang, Y.-H., Chen, P. S., Huang, S., Tzeng, N., Wang, L., Lee, I., Wang, T., Chen, K., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.027 · Cited by 10
Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia
Vetlugina, T. P., Лобачева, О. А., Sergeeva, S. A., Nikitina, V. B., Невидимова, Т. И., & Semke, A. V. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.60 · Cited by 10
The effects of bupropion on negative symptoms in schizophrenia.
Yassini, M., Shariat, N., Sakhvidi, M. N., Amini, F., & Vafaee, M. (2014) · PubMed Central · Cited by 8
Shafti, S. S., & Jahromi, P. F. (2014) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2014/637016 · Cited by 4
Cited by
Ferguson, B. R., & Gao, W.-J. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00037 · Cited by 594
Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia
Brady, R. O., Gonsalvez, I., Lee, I., Öngür, D., Seidman, L. J., Schmahmann, J. D., Eack, S. M., Keshavan, M. S., Pascual-Leone, A., & Halko, M. A. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040429 · Cited by 372
“The development of new interventions for these negative symptoms is hampered by a critical shortfall in our understanding of their pathophysiology, and our ability to modify the functional impact of schizophrenia is further limited by the fact that psychotropic medications have limited efficacy in treating negative sy…”
Predictive processing, source monitoring, and psychosis
Griffin, J. D., & Fletcher, P. C. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045145 · Cited by 133
Adery, L. H., Ichinose, M., Torregrossa, L. J., Wade, J., Nichols, H., Bekele, E., Bian, D., Gizdic, A., Granholm, E., Sarkar, N., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.014 · Cited by 80
Böge, K., Hahne, I., Bergmann, N., Wingenfeld, K., Zierhut, M., Thomas, N., Ta, T. M. T., Bajbouj, M., & Hahn, E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.008 · Cited by 44
Metadata
- Authors
- Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M.
- Venue
- Current Treatment Options in Psychiatry
- Published
- 2016-04-08
- Volume
- 3
- Issue
- 2
- Pages
- 133-150
- ISSN
- 2196-3061 (ISSN-L)
- OpenAlex
- W2318201734
- Cited by
- 167
- References
- 123
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.